Q-omics provides the consensus-scored RNA5SP372 profile across patient tissues and cancer cell-line models. RNA5SP372 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RNA5SP372 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, RNA5SP372 RNA expression shows 6,250 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, THCA, and STAD as cancer lineages where RNA5SP372 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNA5SP372 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNA5SP372 survival associations across molecular data types. RNA5SP372 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNA5SP372 RNA expression–survival associations across cancer types. High RNA5SP372 expression shows unfavorable associations in UCS, CHOL, SKCM and KICH, but favorable associations in KIRP and LAML. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .017). Together, the overview and detailed table identify KIRP as the clearest survival context for RNA5SP372 RNA expression.
This table summarizes RNA5SP372 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNA5SP372. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNA5SP372 shows lower tumor expression in THCA. The THCA box plot shows higher RNA5SP372 RNA expression in normal versus tumor tissue (log2 FC = −0.357, t-test p = .012).
This table shows molecular features associated with RNA5SP372 in patient tissues and cancer cell lines. In patient samples, RNA5SP372 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
